According to the official WeChat account of Zaiding Pharmaceuticals, its partner, Bristol Myers Squibb, announced on February 14th that the US Food and Drug Administration (FDA) has accepted Augtro's supplementary new drug application (sNDA) for the treatment of solid tumor patients aged 12 years and above who have neurotrophic tyrosine receptor kinase (NTRK) gene fusion and are locally advanced or metastatic, Or due to severe illness, surgery cannot remove it. The FDA has granted the application priority review qualification, and the target action date for the Prescription Drug User Payment Act (PDUFA) is June 15, 2024.